Studies of prostate-cancer mortality: caution advised.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.Journal of the National Cancer Institute · 2012
   Trial
2. Mortality results from a randomized prostate-cancer screening trial.The New England journal of medicine · 2009
   Trial
3. Prostate cancer screening: current status and future perspectives.Nature reviews. Urology · 2010
   Review
4. Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells.Cancer gene therapy · 2009
   Article
5. The impact of prostate cancer and hormonal therapy on bone.Reviews in urology · 2009
   Article

Corrections and comments

• Comment on
  Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study.2008

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as